Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Operating Leases: 2019-2025

Historic Operating Leases for CorMedix (CRMD) over the last 7 years, with Sep 2025 value amounting to $2.4 million.

  • CorMedix's Operating Leases rose 333.68% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 333.68%. This contributed to the annual value of $349,091 for FY2024, which is N/A change from last year.
  • Latest data reveals that CorMedix reported Operating Leases of $2.4 million as of Q3 2025, which was up 454.31% from $435,000 recorded in Q2 2025.
  • In the past 5 years, CorMedix's Operating Leases registered a high of $2.4 million during Q3 2025, and its lowest value of $349,091 during Q4 2024.
  • Its 3-year average for Operating Leases is $738,204, with a median of $594,161 in 2023.
  • In the last 5 years, CorMedix's Operating Leases soared by 47,205.04% in 2021 and then plummeted by 31.21% in 2023.
  • Over the past 5 years, CorMedix's Operating Leases (Quarterly) stood at $802,433 in 2021, then increased by 0.07% to $803,000 in 2022, then climbed by 0.01% to $703,000 in 2023, then decreased by 20.91% to $349,091 in 2024, then soared by 333.68% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $435,000 for Q2 2025, and $476,000 during Q1 2025.